Regeneron Pharmaceuticals, Inc (REGN) concluded trading on Thursday at a closing price of $547.36, with 0.46 million shares of worth about $249.81 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -22.09% during that period and on July 03, 2025 the price saw a loss of about -0.07%. Currently the company’s common shares owned by public are about 106.40M shares, out of which, 104.06M shares are available for trading.
Stock saw a price change of 5.06% in past 5 days and over the past one month there was a price change of 12.20%. Year-to-date (YTD), REGN shares are showing a performance of -48.22% which decreased to -23.16% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $476.49 but also hit the highest price of $1211.20 during that period. The average intraday trading volume for Regeneron Pharmaceuticals, Inc shares is 1.36 million. The stock is currently trading 5.33% above its 20-day simple moving average (SMA20), while that difference is down -0.88% for SMA50 and it goes to -23.58% lower than SMA200.
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) currently have 106.40M outstanding shares and institutions hold larger chunk of about 87.20% of that.
The stock has a current market capitalization of $59.10B and its 3Y-monthly beta is at 0.32. PE ratio of stock for trailing 12 months is 13.93, while it has posted earnings per share of $39.29 in the same period. Its PEG reads 10.24 and has Quick Ratio of 4.03 while making debt-to-equity ratio of 0.09. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for REGN, volatility over the week remained 2.98% while standing at 2.82% over the month.
Stock’s fiscal year EPS is expected to drop by -22.44% while it is estimated to increase by 10.53% in next year. EPS is likely to shrink at an annualized rate of 1.36% for next 5-years, compared to annual growth of 15.74% made by the stock over the past 5-years.
Coverage by Wells Fargo stated Regeneron Pharmaceuticals, Inc (REGN) stock as an Equal weight in their note to investors on May 30, 2025, suggesting a price target of $580 for the stock. On May 30, 2025, RBC Capital Mkts Downgrade their recommendations, while on May 14, 2025, Citigroup Upgrade their ratings for the stock with a price target of $700. Stock get an Overweight rating from Cantor Fitzgerald on April 22, 2025.
